Neuren Pharmaceuticals Limited (NEU.AX)
AUD 12.43
(-0.08%)
AUD 12.43
(-0.08%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -17.09 Million AUD | 57.46% |
| 2022 | -40.18 Million AUD | -9.24% |
| 2021 | -36.78 Million AUD | -52.07% |
| 2020 | -24.18 Million AUD | -74.72% |
| 2019 | -13.84 Million AUD | 41.28% |
| 2018 | -23.57 Million AUD | -400.98% |
| 2017 | -4.7 Million AUD | 6.83% |
| 2016 | -5.05 Million AUD | 69.65% |
| 2015 | -16.64 Million AUD | 20.08% |
| 2014 | -20.82 Million AUD | 14.43% |
| 2013 | -24.33 Million AUD | -373.72% |
| 2012 | -5.13 Million AUD | 31.4% |
| 2011 | -7.48 Million AUD | -626.32% |
| 2010 | -1.03 Million AUD | 69.82% |
| 2009 | -3.41 Million AUD | -164.04% |
| 2008 | -1.29 Million AUD | -153.84% |
| 2007 | 2.4 Million AUD | 125.45% |
| 2006 | -9.44 Million AUD | 19.1% |
| 2005 | -11.67 Million AUD | -3587.6% |
| 2004 | -316.59 Thousand AUD | 0.0% |
| 2003 | - AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -2.57 Million AUD | 0.0% |
| 2023 Q4 | -17.09 Million AUD | 0.0% |
| 2023 Q2 | -38.38 Million AUD | 0.0% |
| 2023 FY | -17.09 Million AUD | 57.46% |
| 2022 Q2 | -31.08 Million AUD | 0.0% |
| 2022 Q4 | -40.18 Million AUD | 0.0% |
| 2022 FY | -40.18 Million AUD | -9.24% |
| 2021 FY | -36.78 Million AUD | -52.07% |
| 2021 Q4 | -36.78 Million AUD | 0.0% |
| 2021 Q2 | -18.22 Million AUD | 0.0% |
| 2020 Q2 | -9.17 Million AUD | 0.0% |
| 2020 FY | -24.18 Million AUD | -74.72% |
| 2020 Q4 | -24.18 Million AUD | 0.0% |
| 2019 Q2 | -17.26 Million AUD | 0.0% |
| 2019 FY | -13.84 Million AUD | 41.28% |
| 2019 Q4 | -13.84 Million AUD | 0.0% |
| 2018 Q2 | -11.4 Million AUD | 0.0% |
| 2018 Q4 | -23.57 Million AUD | 0.0% |
| 2018 FY | -23.57 Million AUD | -400.98% |
| 2017 Q4 | -4.7 Million AUD | 0.0% |
| 2017 Q2 | -1.27 Million AUD | 0.0% |
| 2017 FY | -4.7 Million AUD | 6.83% |
| 2016 Q4 | -5.05 Million AUD | 0.0% |
| 2016 FY | -5.05 Million AUD | 69.65% |
| 2016 Q2 | -8.13 Million AUD | 0.0% |
| 2015 Q4 | -16.64 Million AUD | 0.0% |
| 2015 FY | -16.64 Million AUD | 20.08% |
| 2015 Q2 | -17.65 Million AUD | 0.0% |
| 2014 FY | -20.82 Million AUD | 14.43% |
| 2014 Q2 | -22.46 Million AUD | 0.0% |
| 2014 Q4 | -20.82 Million AUD | 0.0% |
| 2013 Q2 | -3.44 Million AUD | 0.0% |
| 2013 FY | -24.33 Million AUD | -373.72% |
| 2013 Q4 | -24.33 Million AUD | 0.0% |
| 2012 FY | -5.13 Million AUD | 31.4% |
| 2012 Q4 | -5.13 Million AUD | 0.0% |
| 2011 Q4 | -7.48 Million AUD | 0.0% |
| 2011 FY | -7.48 Million AUD | -626.32% |
| 2010 Q4 | -1.03 Million AUD | 0.0% |
| 2010 FY | -1.03 Million AUD | 69.82% |
| 2009 FY | -3.41 Million AUD | -164.04% |
| 2009 Q4 | -3.02 Million AUD | 0.0% |
| 2008 Q4 | -1.29 Million AUD | 0.0% |
| 2008 FY | -1.29 Million AUD | -153.84% |
| 2007 Q4 | 2.4 Million AUD | 0.0% |
| 2007 FY | 2.4 Million AUD | 125.45% |
| 2006 FY | -9.44 Million AUD | 19.1% |
| 2006 Q4 | -9.37 Million AUD | 0.0% |
| 2005 Q4 | -23.3 Million AUD | 0.0% |
| 2005 FY | -11.67 Million AUD | -3587.6% |
| 2004 FY | -316.59 Thousand AUD | 0.0% |
| 2003 FY | - AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | -1922.544% |
| Acrux Limited | -1.45 Million AUD | -1072.428% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -837.381% |
| Biome Australia Limited | -1.56 Million AUD | -993.801% |
| BTC Health Limited | -2.02 Million AUD | -745.336% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -459.908% |
| CSL Limited | 15.76 Billion AUD | 100.108% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 87.477% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 90.658% |
| Noxopharm Limited | -2.31 Million AUD | -636.834% |
| PharmAust Limited | -9.71 Million AUD | -75.971% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | -170.31% |
| Prescient Therapeutics Limited | -10.16 Million AUD | -68.203% |
| PYC Therapeutics Limited | -65.76 Million AUD | 74.006% |
| Race Oncology Limited | -17.18 Million AUD | 0.552% |
| Starpharma Holdings Limited | -19.83 Million AUD | 13.806% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 9.55% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 78.446% |
| Memphasys Limited | 4.13 Million AUD | 513.361% |
| Nyrada Inc. | -4.76 Million AUD | -258.412% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -1640.544% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 83.842% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -2309.105% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 437.337% |
| Patrys Limited | -2.24 Million AUD | -662.9% |
| Dimerix Limited | -21.99 Million AUD | 22.271% |
| Orthocell Limited | -19.92 Million AUD | 14.207% |
| Imugene Limited | -91.56 Million AUD | 81.33% |
| Cynata Therapeutics Limited | -6.2 Million AUD | -175.469% |
| Immutep Limited | -122.18 Million AUD | 86.01% |
| Arovella Therapeutics Limited | -12.71 Million AUD | -34.446% |
| Alterity Therapeutics Limited | -12.47 Million AUD | -36.973% |
| Nanollose Limited | -96.22 Thousand AUD | -17664.614% |
| Invex Therapeutics Ltd | -6.02 Million AUD | -183.715% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -245.045% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -1280.319% |
| Biotron Limited | -386.06 Thousand AUD | -4327.717% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 7.973% |
| Tissue Repair Ltd | -16.44 Million AUD | -3.971% |
| AnteoTech Limited | -5 Million AUD | -241.776% |
| Hexima Limited | -2.22 Million AUD | -667.851% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 2.773% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -403.337% |
| Avecho Biotechnology Limited | -5.32 Million AUD | -220.758% |
| Actinogen Medical Limited | -9.13 Million AUD | -87.195% |
| Immuron Limited | -11.48 Million AUD | -48.853% |
| Argenica Therapeutics Limited | -15.91 Million AUD | -7.424% |